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Abstract Cyclosporine A (CsA) is associated with the develop-
ment of cardiovascular toxicity in transplant patients but can
exert myocardial protection against ischemia/reperfusion dam-
ages. We examined in a rat model of chronic CsA administra-
tion whether subtle variations in the NO pathway could account
for these opposite e¡ects. CsA treatment rapidly led to an
increase in myocardial Hsp90 expression promoting the re-
cruitment of Akt and calcineurin, thereby promoting eNOS
activation through Ser1177 phosphorylation and Thr495 dephos-
phorylation, respectively. This was associated with an increase
in myocardial VEGF expression and led to anti-apoptotic e¡ects
in isolated cardiac myocytes. Upon longer CsA exposure, car-
diac toxicity developed, as documented by the in¢ltration of
connective tissue and the increase in iNOS expression. These
later e¡ects were associated with a dramatic decrease in the
abundance and sca¡old function of Hsp90, thereby unraveling
the key role of Hsp90 in governing CsA e¡ects.
3 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Cyclosporine A (CsA) is currently the most widely used
immunosuppressive drug for preventing graft rejection and
autoimmune diseases. The clinical use of CsA and other
agents such as tacrolimus, however, is limited because of the
induced development of nephrotoxicity [1] and hypertension
[2]. Among the mechanisms leading to these side e¡ects, var-
ious alterations in the nitric oxide (NO) signaling pathway
have been identi¢ed as key determinants for the development
of renal and coronary vasculopathies [3^11]. In these studies,
the inhibition by CsA of the activity of a speci¢c NOS iso-
form, e.g. eNOS or iNOS, was identi¢ed as a major trigger
leading to vasodilation impairment. These reports, however,
contrast with studies documenting that CsA might exert ben-
e¢cial e¡ects in the myocardium exposed to ischemia/reperfu-
sion protocols through an eNOS-mediated pathway [12,13].
Other authors have also suggested that the cardiac damages
associated with ischemia/reperfusion and the development of
allograft arteriosclerosis were both prevented by the CsA-in-
duced up-regulation of iNOS [14,15]. Thus, in a given patho-
physiological context, the down- or up-regulation of either
eNOS or iNOS activity seems to determine the deleterious
or bene¢cial impact of immunosuppressive compounds on
the cardiovascular tissues, respectively. Although changes in
iNOS abundance can help to reconcile the above-mentioned
con£icting reports about the role of the mostly transcription-
ally regulated enzyme iNOS, other factors need to be consid-
ered to evaluate the e¡ects of CsA on the eNOS activity.
Activation of the endothelial NOS isoform is, indeed, not
only dependent on the enzyme abundance [10,11] but is also
exquisitely regulated through post-translational interactions
with proteins such as caveolin and the heat shock protein
Hsp90 [16] as well as via site-speci¢c phosphorylations (see
[17] for references). Accordingly, the phosphorylation of
eNOS on the serine 1177 has been extensively documented
as a major kinase-dependent mode of eNOS activation,
whereas two other sites within the eNOS sequence, e.g. Thr
495 and Ser 116, have been reported to participate, when
phosphorylated, in the tonic inhibition of eNOS activity (see
[17] for references). We previously reported that these di¡er-
ent modes of regulation could interplay with each other. For
instance, Hsp90 acts as a sca¡old to recruit Akt in the eNOS
complex and thereby promotes the phosphorylation of eNOS
on serine 1177 [18]. Interestingly, Hsp90 was also reported to
interact with calcineurin [19], a phosphatase thought to regu-
late eNOS dephosphorylation [20,21], although the demon-
stration of a direct relationship between these three proteins
has never been given.
In this study, we therefore set up a model of chronic CsA
administration in rats in order to evaluate the regulatory role
of Hsp90 in the myocardium and of the changes in the phos-
phorylation status of eNOS. We also looked for modi¢cations
in VEGF and iNOS expressions as hallmarks of the potential
protective and deleterious pathways induced by CsA treat-
ment, respectively. The VEGF induction seems to be a com-
mon pro-survival pathway activated in response to a large
variety of cellular insults and its protective e¡ects are medi-
ated through several of the eNOS modulators including Akt
and calcineurin [18,22]. A direct link between all these di¡er-
ent actors, however, has never been established in the context
of CsA treatment. Conversely, iNOS is usually associated with
late stages of cardiac diseases (when eNOS is down-regulated)
and its expression level was therefore examined here in the
light of morphological cardiac alterations; direct measure-
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ments of apoptosis were also carried out in an in vitro model
of CsA-exposed cardiac myocytes.
2. Materials and methods
2.1. Animals, treatment and sample preparation
The study included 48 Wistar rats with a weight of 200^250 g. Each
procedure was approved by the local authorities according to national
animal care regulations. The animals were divided into four groups
(of 12 animals each). The control animals were daily injected subcuta-
neously with olive oil for 21, 42 and 63 days (four animals for each
period). The animals of the other groups were daily injected (s.c.) with
CsA (Sandimmun, Sandoz; 15 mg kg31 in olive oil) for 21, 42 and 63
days, as previously described [23]. The animals were killed at the end
of the treatment periods. The hearts were removed, washed in PBS
and cut transversely into small pieces. Some samples were ¢xed ac-
cording to standard procedures, embedded in para⁄n and serially
sliced for immunohistochemical study. In some experiments, neonatal
mouse cardiac myocytes were isolated and cultured as previously de-
scribed [24].
2.2. Immunohistochemical study
Heart sections were probed with antibodies against Hsp90, iNOS,
eNOS, and VEGF (BD Transduction Labs) and with Sirius Red (to
stain collagen). Brie£y, 5 Wm thick sections were ¢rst depara⁄nized
and rehydrated, and then immersed in 3% hydrogen peroxide in meth-
anol for 30 min to block the endogenous peroxidase activity. Sections
were then incubated with goat or rabbit serum (diluted 1:5) for 60
min, then serially treated with HSP90 (goat polyclonal, diluted 1:10),
iNOS, eNOS (rabbit polyclonal, diluted 1:50), and VEGF
(VEGF121: goat polyclonal, diluted 1:10) at 4‡C overnight. The sec-
tions were washed in TBS bu¡er and sequentially incubated with bio-
tinylated secondary antibodies, and avidin^biotin horseradish peroxi-
dase complex according to the manufacturer’s instructions (ABC kit,
Dakopatts, Milan, Italy). The sections were stained by immersion in a
solution of 0.05% 3,3-diaminobenzidine tetrahydrochloride and 0.03%
hydrogen peroxide. All slides were counterstained with hematoxylin,
dehydrated and mounted. Control reactions were performed in the
absence of the primary antibodies.
2.3. Immunoprecipitation and immunoblotting
Liquid nitrogen-frozen rat heart pieces or cultured neonatal myo-
cytes were homogenized by using an Ultra-Turrax and a sonicator.
The lysis bu¡er contained 60 mM octylglucoside, 50 mM Tris^HCl
(pH 7.4), 125 mM NaCl, 2 mM dithiothreitol, 100 WM EGTA as well
as protease and phosphatase inhihibitor cocktails (Sigma). Lysates
were centrifuged at 1000Ug and the supernatants processed for im-
munoblotting (IB) or immunoprecipitation (IP), as described previ-
ously [16,18]. In the IP experiments, we used the lysis bu¡er for the
incubations with the antibodies and the protein G^Sepharose beads
(as well as for the washing steps). The eNOS, iNOS and Hsp90 anti-
bodies were from BD Transduction Labs; Akt, calcineurin, phospho-
caspase-3 and caspase-3 antibodies from BD PharMingen, and phos-
pho-eNOS antibodies from NEB Cell Signaling Technology or Up-
state Biotechnology Inc.
2.4. Statistical methods
The results are given as meanRS.E.M.; for the IB experiments,
data were normalized for the amounts of protein in the dish. Statis-
tical analyses of results between experimental groups were performed
with one-way analysis of variance (ANOVA) and the Student^New-
man^Keul post-test.
3. Results
We ¢rst performed a series of immunoblot experiments us-
ing lysates from myocardium of CsA-treated and untreated
rats. As shown in the upper panel of Fig. 1A (see also bar
graph, Fig. 1B), the abundance of Hsp90 was found to be
increased by almost three-fold as soon as 21 days after initia-
tion of CsA administration. Longer exposure to CsA led to a
progressive decrease in Hsp90 expression to reach a value
Fig. 1. E¡ects of CsA exposure on eNOS and Hsp90 expression
and on the phosphorylation of eNOS on Ser 1177 and Thr 495.
Hearts from rats treated, or not, with CsA for 0, 21, 42 and 63
days were collected. A: Lysates from CsA-treated heart were immu-
noblotted (IB) with antibodies directed against eNOS, Hsp90 and
eNOS phosphorylated on the indicated residues. B: Bar graph rep-
resents the relative expression of eNOS, Hsp90, phospho-Ser 1177
and -Thr 495 eNOS determined by densitometric analyses of di¡er-
ent IB as the ratio between rats treated or not with CsA; *P6 0.05,
**P6 0.01 vs. day 0, #P6 0.05, ##P6 0.01 vs. day 21 (n=4).
Fig. 2. E¡ects of CsA exposure on the Hsp90-mediated formation
of a multiprotein complex between eNOS, Akt and calcineurin.
Hearts from rats treated, or not, with CsA for 0, 21, 42 and 63
days were collected. A: Lysates from CsA-treated heart were immu-
noprecipitated (IP) with Hsp90 antibodies and then immunoblotted
(IB) with antibodies directed against Akt and calcineurin. B: Ly-
sates from 21-day CsA-treated heart were precleared, or not, by im-
munoprecipitation with Hsp90 antibodies, and then a new immuno-
precipitation was carried out with eNOS antibodies before
immunoblotting with Akt and calcineurin antibodies. These experi-
ments were consistently reproduced with lysates isolated from di¡er-
ent rats (n=4; max. values at day 21 are given in the text).
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below the control level after 63 weeks (73 R 5% vs. control)
(Fig. 1B). Although we did not observe any signi¢cant change
in eNOS expression when compared with the values at day 0,
the di¡erence in eNOS expression between day 21 and 63 of
CsA treatment was statistically signi¢cant (P6 0.05). These
changes were not attributable to aging, since in control rats
(sham-treated or untreated) sacri¢ced at the same age, we did
not identify a di¡erence in eNOS abundance between day 0,
21, 42 and 63. We also studied the impact of CsA exposure on
the phosphorylation status of eNOS. Fig. 1A (lower panel)
shows that the phosphorylation of eNOS on Ser 1177 was
maximal at day 21 and then rapidly decreased to be undetect-
able after 63 days of CsA treatment. A mirror image was
obtained for the extent of eNOS phosphorylation on Thr
Fig. 3. Morphological and immunohistochemical analyses of rat myocardium exposed to CsA. A: Slices from ventricles of rats treated with
CsA for 0, 21 and 63 days were colored with Sirius red to detect the presence of connective tissues or immunostained with antibodies directed
against iNOS, VEGF and Hsp90, as indicated. B: Quantitative analyses of the expression of VEGF and iNOS (as detected by IH) are pre-
sented in bar graphs; **P6 0.01 vs. day 0 (n=4).
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495, e.g. minimal after 21 days and maximal at day 63 (see
Fig. 1A,B).
We then evaluated whether the transient CsA-induced over-
expression of Hsp90 could account for changes in the ability
of the kinase Akt and the phosphatase calcineurin to alter the
phosphorylation status of eNOS (see Section 1). As shown in
Fig. 2A, the patterns of interaction with Akt and calcineurin
exactly re£ected the bell-shaped changes in Hsp90 with a max-
imum at day 21 (3.6- and 2.1-fold increase versus day 0, re-
spectively; P6 0.01; n=3) and then a progressive decrease
with time of exposure to CsA. We also examined whether,
in our model, Hsp90 could act as an adaptor recruiting Akt
and calcineurin in the eNOS complex. Accordingly, we per-
formed immunoprecipitation with eNOS antibodies either
from total lysates or from Hsp90-precleared lysates, e.g. de-
pleted of Hsp90 by immunoprecipitation. Fig. 2B reveals that,
while Akt and calcineurin were found to be associated with
eNOS in control lysates, Hsp90 preclearing led to the disap-
pearance of both regulatory proteins from the eNOS complex.
We also performed morphological and immunohistochem-
ical (IH) analyses of rat myocardium at di¡erent times of CsA
treatment. Accordingly, hearts from control rats or rats
treated for 21 days with CsA revealed a normal morphology,
consisting of striated muscle ¢bers and scarce connective tis-
sue (see Fig. 3A). By contrast, hearts from rats treated for 63
days with CsA showed clear degenerative changes with muscle
¢ber disorganization and abundant Sirius red-stained connec-
tive tissues (+280%, P6 0.01, n=4) (Fig. 3A). Importantly,
CsA treatment and not aging accounted for these changes, as
validated by the lack of myocardium degeneration when com-
paring hearts from sham rats at day 0 and 63 (data not
shown). The morphological pattern after 42 days of CsA
treatment was intermediary, although closer from the 21-day
condition, suggesting that the cytotoxic potential of this drug
needed a certain delay to exert its e¡ects or that cytoprotective
e¡ects of CsA could fade with time.
To address these non-exclusive hypotheses, we examined
whether CsA could induce changes in the myocardial expres-
sion of the inducible NOS isoform (iNOS) and of the VEGF/
eNOS pathway. We observed a dramatic up-regulation of
iNOS at day 63 of CsA exposure, whereas VEGF (121-kDa
isoform) expression was up-regulated at day 21 of CsA treat-
ment and then decreased to basal levels (Fig. 3A,B). By con-
trast, in the limits of our quantitative immunohistochemical
analysis, we did not observe signi¢cant changes in the expres-
sion of eNOS: its abundance was found unaltered by CsA
treatment in cardiac myocyte and microvascular endothelial
cells (although present at much higher levels in the latter).
Data presented in Fig. 3A also con¢rmed that a transient,
although dramatic, increase in the myocardial expression of
Hsp90 was detectable upon 21 days of CsA exposure.
To more de¢nitely establish the link between the increase in
Hsp90 and the cytoprotective e¡ects of CsA, we pre-treated
mouse neonatal cardiac myocytes with CsA (1 WM) and ex-
amined the level of apoptosis induced by serum deprivation.
Accordingly, the detection of the active 17-kDa form of cas-
pase-3 was performed in parallel to the immunoblotting of the
32-kDa (uncleaved) pro-caspase-3. Fig. 4 shows that the CsA-
induced increase in Hsp90 expression (+193%, P6 0.05, n=3)
was associated with lesser amounts of active caspase-3 (397%,
P6 0.05, n=3). Importantly, the treatments with geldanamy-
cin or L-NAME did not signi¢cantly alter the relative CsA-
induced increase in Hsp90 (+180% and +146%, respectively;
P6 0.05, n=3) but completely abrogated the anti-apoptotic
e¡ects of CsA exposure (i.e. they did not prevent the cleavage
of pro-caspase-3) (Ps 0.1 vs untreated myocytes, n=3).
4. Discussion
In the present study we found that CsA treatment could
induce changes in the post-translational regulation of eNOS in
rat myocardium. Accordingly, we have documented that 21-
day exposure to CsA led to the activation of eNOS through
Ser 1177 phosphorylation and Thr 495 dephosphorylation.
These changes preceded the development of cardiac toxicity
(max. at 63 days of treatment), as authenticated in our model
by the down-regulation of VEGF, the induction of iNOS and
the connective tissue in¢ltration. This late phase of CsA ef-
fects was also associated with a progressive decrease in the
eNOS interaction with Akt and calcineurin, as revealed by the
reduction in the extent of the Ser 1177 phosphorylation and
the tonic phosphorylation of Thr 495, respectively. Impor-
tantly, we provided mechanistic insights on how changes in
Hsp90 expression can orchestrate these changes in eNOS post-
translational regulation during CsA treatment.
The expression of Hsp90 appeared, indeed, to be dramati-
cally in£uenced by the time of exposure to CsA. Hsp90 ex-
pression peaked at 21 days after the initiation of the immu-
nosuppressive treatment. This was paralleled by a strong up-
regulation of VEGF, a well-characterized activator of the
Hsp90^eNOS pathway [18,25]. Together with the observation
that Hsp90 acts as an adaptor recruiting Akt and calcineurin
in the eNOS complex, these data indicate that a strong acti-
vation of eNOS occurred at this early stage of CsA treatment.
Indeed, eNOS phosphorylation on Ser 1177 and dephosphor-
ylation on Thr 495 have been extensively documented to pro-
mote a sustained NO production by increasing the calmodulin
a⁄nity and improving the electron £ux through the enzyme
[26^28]. In our study, this Hsp90-driven eNOS-activation
phase was associated with a myocardium devoid of any mor-
phological alterations or ¢brosis and can therefore be corre-
lated with the previously reported NO-mediated protective
e¡ects of CsA after ischemia/reperfusion [12,13]. Furthermore,
using cultured neonatal cardiac myocytes, we showed that
CsA could rapidly induce an increase in Hsp90 abundance
and thereby protect these cells against apoptosis induced by
serum deprivation (see Fig. 4). Altogether, these data indicate
Fig. 4. E¡ects of CsA exposure on the Hsp90-mediated NO-depen-
dent protection against serum deprivation-induced apoptosis. Cul-
tured neonatal cardiac myocytes were treated or not with CsA for
48 h, then exposed to serum-deprived medium for the next 36 h.
Lysates were immunoblotted (IB) with antibodies directed against
Hsp90, active (cleaved) caspase-3 and pro-caspase-3. These experi-
ments were repeated with lysates prepared from three di¡erent cul-
tures of isolated myocytes (signi¢cant di¡erences derived from densi-
tometric analyses are given in the text).
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that Hsp90 acts as an important control point to determine
the fate of (cardiac) tissues responding to a stress by inducing
pro-survival pathways before being overwhelmed by toxicity.
It is also noteworthy that the well-known inhibitory e¡ects
of CsA on calcineurin [29] can apparently be counterbalanced
by the myocardial up-regulation of Hsp90, leading to the
recruitment and activation of this phosphatase in the eNOS
complex. Recent reports [20,21] of the CsA-induced inactiva-
tion of eNOS through an inhibition of calcineurin, and the
associated blockade of eNOS dephosphorylation, need there-
fore to be interpreted with caution. In fact, our study brings
the concept of a compartmentation-like e¡ect allowing calci-
neurin to exert its activity, whereas an overall inhibition of the
phosphatase is driven by the CsA exposure.
In conclusion, the observation of the CsA-induced changes
in Hsp90 expression, i.e. ¢rst increased three-fold then re-
duced below basal levels, brings some rationale to the very
puzzling issue of the balance between the bene¢cial, tissue-
protective e¡ects of CsA and the cardiovascular toxicity of
this immunosuppresive drug. Moreover, the identi¢cation of
Hsp90 acting as a sca¡old to recruit not only Akt [18] but also
calcineurin (this study) in the eNOS complex allows us to
understand how eNOS can simultaneously be phosphorylated
and dephosphorylated at two very distinct sites (both modi¢-
cations leading to the enzyme activation). Improving Hsp90
function therefore appears to be a very promising therapeutic
strategy to prevent eNOS inactivation in various disease states
characterized by endothelial dysfunction.
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